How does FDA and EMA sharing global regulatory leadership affect company?
FDA and EMA collaboration supports OS Therapies' global market access strategy The collaborative environment between the FDA and the European Medicines Agency allows OS Therapies to pursue a harmonized global early market access strategy for its lead asset, OST-HER2. This includes seeking a Biologics License Application (BLA) from the U.S. FDA and Conditional Marketing Authorisation Applications (CMAA) from the EMA. The companies are leveraging designations such as Orphan Drug Designation (ODD) and Fast Track Designation (FTD) to advance the product through various international review processes.
- Effect
- Strong positive
- How direct
- 2 steps, all reported
- When
- Right away
- The story
- Gone quiet
How it reaches company
-
The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have shared the global regulatory leadership mantle. This discussion followed a U.K. MHRA Scientific Advice Meeting regarding a confirmatory Phase 3 trial. The leadership sharing is linked to Project Orbis, through which the FDA has approved products from the U.K. leadership.
The full event1independent outlet -
The U.S. FDA has aligned with OS Therapies on the proposed adaptive design of the pending Phase 3 study. This alignment is crucial as the company is seeking a BLA from the FDA for OST-HER2 in osteosarcoma in 2026.
1 report connects these two. Brind only summarizes; follow a link to read the reporting itself.
- intelligencer.ca Sep 21
-
Leveraging the global regulatory leadership discussions, the company is pursuing a BLA under the Accelerated Approval Program in the U.S., followed by CMAAs in Europe, and applications to the Australian Therapeutic Goods Agency (TGA). This strategy is supported by the company's successful Phase 2b clinical trial data showing clinically significant benefit in the 12-month event free survival endpoint.
1 report connects these two. Brind only summarizes; follow a link to read the reporting itself.
- intelligencer.ca Sep 21
-
legal entity representing an association of people, whether natural, legal or a mixture of both, with a specific objective
Everything about company
Tap any step to see the evidence behind it.
The facts so far
As reported. Each one links to where it comes from.
- The company is seeking a Biologics License Application (BLA) from the U.S. FDA for OST-HER2 in osteosarcoma in 2026.intelligencer.ca
- The company is seeking Conditional Marketing Authorisation Applications from the U.K.’s Medicines and Healthcare products Regulatory Agency and the EMA for OST-HER2 in 2026.intelligencer.ca
- OST-HER2 has received Orphan Drug Designation (ODD), Fast Track Designation (FTD) and Rare Pediatric Disease Designation (RPDD) from the U.S. Food & Drug Administration.intelligencer.ca
- The company is leveraging the successful Phase 2b clinical trial data showing clinically significant benefit in the 12-month event free survival endpoint.intelligencer.ca
Why it matters
For OS Therapies, the successful navigation of the FDA and EMA review processes is critical to the commercial viability of its lead asset, OST-HER2. The company is focused on achieving market access in the U.S., Europe, and Australia, which represents its primary commercial targets.
This approach mirrors the global trend of leveraging international regulatory cooperation to accelerate drug development. By utilizing designations like ODD and FTD, the company is attempting to streamline the path to market for ultra orphan diseases, a common challenge in rare cancer treatments.
What we don't know yet
- What are the specific outcomes of the pending BLA and CMAA applications?
- How will the company utilize the Priority Review Vouchers it gains through the BLA process?
What would change this answer
Reporting
- intelligencer.caSep 21
Keep going
Brind's analysis is written by AI from the reporting linked above and can be wrong. It explains possible effects; it is not investment advice.